Roivant Sciences Ltd.
ROIV
Pozycja w akcjach
#981
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Cena akcji
$33.73
Ostatnia synchronizacja: 2026-07-31
Kapitalizacja rynkowa
$24.37B
Zmiana (1 dzień)
-2.28%
Zmiana (1 rok)
95.44%
Kraj
GB
Handel Roivant Sciences Ltd. (ROIV)
Kategoria
Healthcare
EPS dla Roivant Sciences Ltd. (ROIV)
EPS na dzień June 2026 TTM: $-0.38
Według najnowszych raportów finansowych i ceny akcji firmy Roivant Sciences Ltd., obecny EPS (TTM) wynosi $-0.38. Na koniec roku 2024 firma miała EPS w wysokości $5.55, wzrost w porównaniu do do EPS z roku 2023, który wynosił $-1.42.
Historia EPS dla Roivant Sciences Ltd. od 2020 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-0.38 | 58.33% |
| 2025 | $-0.24 | -104.32% |
| 2024 | $5.55 | -490.85% |
| 2023 | $-1.42 | 12.70% |
| 2022 | $-1.26 | 6.78% |
| 2021 | $-1.18 | -167.43% |
| 2020 | $1.75 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -4,657.89% |
US
|
|
| $-7.98 | 2,000.00% |
US
|
|
| $-5.29 | 1,292.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,400.00% |
NL
|
